A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Notch Suppresses Angiogenesis and Progression of Hepatic Metastases

(2015) D. Banerjee et al.   CANCER RESEARCH

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

(2015) W.-C. Yen et al.   CLINICAL CANCER RESEARCH

Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

(2015) Eileen Mary O'Reilly et al.   JOURNAL OF CLINICAL ONCOLOGY

Stem cells living with a Notch

(2013) U. Koch et al.   DEVELOPMENT

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Notch3 and Hey-1 as Prognostic Biomarkers in Pancreatic Adenocarcinoma

(2012) Christopher D. Mann et al.   PLoS One

Notch and Kras in pancreatic cancer: At the crossroads of mutation, differentiation and signaling

(2011) Jean-Paul De La O et al.   CELL CYCLE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Notch1 Functions as a Tumor Suppressor in a Model of K-ras–Induced Pancreatic Ductal Adenocarcinoma

(2010) Linda Hanlon et al.   CANCER RESEARCH

Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma

(2010) P. K. Mazur et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma

(2009) Ruben Plentz et al.   GASTROENTEROLOGY

CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells

(2009) Sung Pil Hong et al.   INTERNATIONAL JOURNAL OF CANCER

Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway

(2009) Jun Yao et al.   MEDICAL ONCOLOGY

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

(2008) Juliana Hamzah et al.   NATURE

Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy

(2008) Scott J. Dylla et al.   PLoS One